Pharmacological concentrations of ascorbate radiosensitize glioblastoma multiforme primary cells by increasing oxidative DNA damage and inhibiting G2/M arrest

This publication has 48 references indexed in Scilit:

• BMI1 Confers Radioresistance to Normal and Cancerous Neural Stem Cells through Recruitment of the DNA Damage Response Machinery
  Journal of Neuroscience, 2010
• Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial
  The Lancet Oncology, 2009
• Intravenously administered vitamin C as cancer therapy: three cases
  Canadian Medical Association Journal, 2006
• Manganese Superoxide Dismutase-Mediated Gene Expression in Radiation-Induced Adaptive Responses
  Molecular and Cellular Biology, 2003
• Effector Genes Altered in MCF-7 Human Breast Cancer Cells after Exposure to Fractionated Ionizing Radiation
  Radiation Research, 2001
• High-Dose Vitamin C versus Placebo in the Treatment of Patients with Advanced Cancer Who Have Had No Prior Chemotherapy
  New England Journal of Medicine, 1985
• Failure of High-Dose Vitamin C (Ascorbic Acid) Therapy to Benefit Patients with Advanced Cancer
  New England Journal of Medicine, 1979
• Supplemental ascorbate in the supportive treatment of cancer: Reevaluation of prolongation of survival times in terminal human cancer
  Proceedings of the National Academy of Sciences, 1978
• Supplemental ascorbate in the supportive treatment of cancer: Prolongation of survival times in terminal human cancer.
  Proceedings of the National Academy of Sciences, 1976
• The orthomolecular treatment of cancer II. Clinical trial of high-dose ascorbic acid supplements in advanced human cancer
  Chemico-Biological Interactions, 1974